期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (1)
Background The prevalence of posttraumatic stress disorder (PTSD) co-occurring in people with bipolar disorder (BD) is high. People with BD and PTSD m......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (7)
Background BTRX-246040, a nociceptin/orphanin FQ peptide receptor antagonist, is being developed for the treatment of depressive patients. However, th......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (2)
Background: Epigenetic modifications like DNA methylation are understood as an intermediary between environmental factors and neurobiology. Cerebral m......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (7)
Background Evidence has accumulated demonstrating the existence of opioid receptor heteromers, and recent data suggest that targeting these heteromers......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (11)
Background: Dopamine plays a key role in several physiological functions such as motor control, learning and memory, and motivation and reward. The at......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (12)
Background N-methyl-D-aspartate receptors (NMDARs) are crucial components of brain function involved in memory and neurotransmission. Sodium benzoate ......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (2)
Background Lysergic acid diethylamide (LSD) is currently being investigated in psychedelic-assisted therapy. LSD has a long duration of acute action o......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (2)
Background Oxidative stress and oxidation-induced DNA damage may contribute to the pathophysiology of depression. Two key mediators of base excision r......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (9)
Background Alzheimer disease (AD) and depression often cooccur, and inhibition of phosphodiesterase-4 (PDE4) has been shown to ameliorate neurodegener......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (5)
Background Impulse control disorder has been suggested to meet the criteria of addiction and is often considered a behavioral addiction; however, few ......
期刊： INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023; 26 (4)
Background Ketamine has considerable therapeutic potential in alleviating major depressive disorder and chronic suicidality. However, the clinical dia......
